Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2001-02-23
2009-06-16
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S193100, C424S196110, C424S197110, C424S542000, C435S026000, C435S326000, C435S346000, C436S057000, C436S064000, C436S086000, C436S164000, C436S166000, C436S172000, C514S001000, C514S002600, C514S004300
Reexamination Certificate
active
07547441
ABSTRACT:
A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalent or mimetic thereof, which PAI-2 is bound, linked, or otherwise associated with a toxin or label.
REFERENCES:
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5422090 (1995-06-01), Stephens et al.
patent: 5679350 (1997-10-01), Jankun et al.
patent: 6348185 (2002-02-01), Piwnica-Worms
Lazar, Eliane et al. Transforming Growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities, Molecular and Cellular 8(3): 1247-1252, Mar. 1988.
Tsatas et al. Tissue-specific expression of the relaxed conformation of plasminogen activator inhibitor-2 and low-density lipoprotein receptor-related protein in human term gestational tissues. The Journal of Histochemistry and Cytochemistry 45(12): 1593-1602, 1997.
Conese and Blasi. Urokinase/Urokinase Receptor System: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe-Seyler 376: 143-155, Mar. 1995.
Ye et al., “cDNA Cloning and Expression inEscherichia coliof a Plasminogen Activator Inhibitor from Human Placenta”, Journal of Biological Chemistry, vol. 262 (8): 3718-3725 (Mar. 15, 1987).
Antalis et al.; Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor, Proc. Natl. Acad. Sci. USA, vol. 85: 985-989 (Feb. 1988).
Jensen et al., Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and Factor XIIIa;Transglutaminase-catalyzed cross-linking to cellular and extracellular structures, Eur. J. Biochem., 214: 141-146 (1993).
Saunders et al., Immunological Detection of Conformational Neoepitopes Associated with the Serpin Activity of Plasminogen Activator Inhibitor Type-2, Journal of Biological Chemistry, vol. 273 (18): 10965-10971 (May 1, 1998).
Ragno et al., Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells, Eur. J. Biochem., 233: 514-519 (1995).
Schmitt et al., The urokinase plasminogen activator system as a novel target for tumor therapy, Fibrinolysis & Proteolysis, 14(2/3): 114-132 (2000).
Hermans et al., Inhibition of Acrosin by Serpins, A Suicide Substrate Mechanism, Biochemistry, 34: 3678-3685 (1995).
Jankova et al., Crystal Structure of the Complex of Plasminogen Activator Inhibitor 2 with a Peptide Mimicking the Reactive Center Loop, Journal of Biological Chemistry, vol. 276 (46): 43374-43382 (Nov. 16, 2001).
Andronicos et al., The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein, Biochimica et Biophysica Acta 1337: 27-39 (1997).
Saunders et al., Interaction between the P14 Residue and Strand 2 of β-Sheet B Is Critical for Reactive Center Loop Insertion in Plasminogen Activator Inhibitor-2, Journal of Biological Chemistry, vol. 276 (46): 43383-43389 (Nov. 16, 2001).
Jensen et al., Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells, Cell Regulation, vol. 1, 1043-1056 (Dec. 1990).
Hermanson, Bioconjugate Techniques, Bifunctional Chelating Agents and Radioimmunoconjugates, 365 (Academic Press 1996).
International Search Report, Mar. 9, 2004.
B.J. Allen et al., “In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers”, Critical Reviews in Oncology/Hematology, Elsevier Science Ireland Ltd., Limerick, Ireland, vol. 39, No. 1-2, Jul. 2001, pp. 139-146.
B.J. Allen et al., “Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer”, Australasian Radiology, Blackwell Science Ltd., AU, vol. 43, 1999, pp. 480-486.
Jean Maublant, “Scintigraphic imaging of breast tumors”, European Journal of Radiology, Ireland Jan.I 1997, vol. 24, No. 1/1997, pp. 2-10.
B.J. Allen et al., Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149, Nuclear Medicine Communications, © 1996 Chapman and Hall Ltd., pp. 40-47, (1996).
B.J. Allen et al., “Can alpha-immunotherapy succeed where other systemic modalities have failed?”, Nuclear Medicine Communications (20), © 1999 Lippincott Williams & Wilkins, pp. 205-207, (1999).
Peter A. Andreasen et al., “The Urokinase-Type Plasminogen Activator System in Cancer Metastasis: a Review”, Int. J. Cancer: 72, © 1977 Wiley-Liss, Inc., pp. 1-22, (1977).
Duffy, Michael J. et al., “Urokinase Plasminogen Activator: A Prognostic Mqrker in Multiple in Multiple Types of Cancer”, Journal of Surgical Oncology (71), © 1999 Wiley-Liss, Inc., pp. 130-135, (1999).
Foekens, John A. et al., Plasminogen Activator Inhibitor-2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer1, Cancer Research (55), pp. 1423-1427, (Apr. 1, 1995).
Hang, M.T.N., et al., “Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control an dtumor xenograft-bearing mice”, Fibrinolysis & Proteolysis 12(3), © Harcurt Brace & Co., Ltd., pp. 145-154, (1998).
Jankun, Jerzy et al., “Antitumor Activity of the Type 1 Plasminogen Activator Inhibitor Cytotixic Conjugate in Vitro1,” Advances in Brief, PAI-2 Project, pp. 5829-5832, Oct. 15, 1992.
Kennel, SJ et al., “Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi”, British Journal of Cancer 80(1/2), © 1999 Cancer Reserach Campaign, pp. 175-184, (1999).
Kruithof, Egbert K.O., “Biological and Clinical Aspects of Plasminogen Activitor Inhibitor Type 2”, Blood vol. 86, No. 11, © 1995 The American Society of Hematology, pp. 4007-4024, (Dec. 1, 1995).
Laug, Walter E. et al., Inhibition of Invasion of HT1080 Sarcoma Cells Expressing recmbinant Plasminogen Activator Inhibitor 21,. Cancer Research 53, pp. 6051-6057, (Dec. 15, 1993).
Lloyd, E.L. et al., “Cell survival following multiple-track alpha particle irradiation”, Int. J. Radiat. Biol. vol. 35, No. 1, pp. 23-31, (1979).
Mueller, Barbara M. et al., “Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis inscid/scidmice”, Proc. Natl. Acad. Sci. USA 92, pp. 205-209, (Jan. 1995).
Poellaenen, Jari et al., “Directed Plasminogen Activation at the Surface of Normal and Malignant Cells”, Advances in Cancer Research, vol. 57, © 1991 Academic Press, Inc., pp. 273-328.
Ranson, M. et al., “Increased plasminogen binding is associated with metastativc breast cancer cells: differential expression of plasminogen binding proteins”, © 1998 Cancer Research Campaign, pp. 1586-1597.
Schmitt, M. et al., “Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy”, Thrombosis and Haemostasis 78(1), © F.K. Schattauer Verlagsgesellschaft mbH, pp. 285-296, (1997).
Yang, Jia-Lin et al., “Urokinase-Type Plasminogen Activator and its Receptor in Cololrectal Cancer: Independent Prognostic Factors of Metastasis and Cancer-Specific Survival and Potential Therapeutic Targets”, Int. J. Cancer (Pred. Oncol.) 89, pp. 431-439, (2000).
Allen Barry John
Bunn Clive Leighton
Ranson Marie
Foley & Lardner LLP
Harris Alana M.
Medical Scitec Australia Pty Ltd
PAI-2 Pty Limited
University of Wollongong
LandOfFree
PAI-2 conjugates for the treatment and imaging of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PAI-2 conjugates for the treatment and imaging of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PAI-2 conjugates for the treatment and imaging of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4139643